US 11,718,642 B2
Compositions and methods for treating CNS disorders
Albert Jean Robichaud, Boston, MA (US); Francesco G. Salituro, Marlborough, MA (US); Maria Jesus Blanco-Pillado, Arlington, MA (US); Daniel La, Chestnut Hill, MA (US); and Boyd L. Harrison, Princeton Junction, NJ (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 16/961,097
Filed by Sage Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Jan. 11, 2019, PCT No. PCT/US2019/013315
§ 371(c)(1), (2) Date Jul. 9, 2020,
PCT Pub. No. WO2019/140272, PCT Pub. Date Jul. 18, 2019.
Claims priority of provisional application 62/728,514, filed on Sep. 7, 2018.
Claims priority of provisional application 62/616,768, filed on Jan. 12, 2018.
Claims priority of provisional application 62/617,134, filed on Jan. 12, 2018.
Prior Publication US 2020/0354399 A1, Nov. 12, 2020
Int. Cl. A61K 31/352 (2006.01); A61K 31/382 (2006.01); A61K 31/385 (2006.01); A61K 31/39 (2006.01); A61K 31/435 (2006.01); A61K 31/498 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); A61K 31/53 (2006.01); A61K 31/536 (2006.01); A61K 31/415 (2006.01); C07D 221/08 (2006.01); C07D 237/26 (2006.01); C07D 239/70 (2006.01); C07D 241/36 (2006.01); C07D 253/08 (2006.01); C07D 265/02 (2006.01); C07D 265/12 (2006.01); C07D 265/34 (2006.01); C07D 279/02 (2006.01); C07D 279/08 (2006.01); C07D 279/14 (2006.01); C07D 291/08 (2006.01); C07D 311/78 (2006.01); C07D 319/02 (2006.01); C07D 319/08 (2006.01); C07D 319/14 (2006.01); C07D 323/04 (2006.01); C07D 327/06 (2006.01); C07D 327/10 (2006.01); C07D 335/04 (2006.01); C07D 339/08 (2006.01); C07D 341/00 (2006.01); C07D 401/06 (2006.01); C07D 405/14 (2006.01); C07D 407/14 (2006.01); C07D 409/14 (2006.01); C07D 411/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 419/14 (2006.01); C07J 73/00 (2006.01)
CPC C07J 73/003 (2013.01) 13 Claims
 
1. A compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
m is 0, 1, 2, or 3;
p is 0, 1, or 2; and
each R32 is independently halogen, C1-6 alkyl, hydroxyl, or cyano.